$INV founder slams Innventure leadership as "self-dealing destroyers of shareholder value" despite Accelsius breakout potential.
A vocal shareholder—who claims to have built a $1B+ revenue company with 90% market share—unloaded on Innventure management, calling out former CEO Otworth for alleged fraud, unjust enrichment suits, and installing an "inexperienced patsy" as his successor.
Key allegations:
• Share count ballooned from ~50M to 80M+ through "perpetual dilution"
• Management enriched insiders via related-party deals, bogus stock grants, and undisclosed payments to Vital Energy drink
• Despite Accelsius's last funding round implying $INV should trade above $3/share, stock languishes at a "massive discount" due to management reputation
The bright spot: Accelsius, the two-phase cooling play led by Josh Claman, is "in pole position" and could hit $4B market cap if execution continues.
The shareholder's prescription for new CEO Bill Grieco:
1. Fire CFO Roland Austrup to "clear the stench"
2. Slash overhead 95% to $3M/year max
3. Sell or shut down AeroFlex and Refinery
4. Stop dilution, related-party transactions, and claw back Vital Energy payments
5. Get out of Accelsius's way—let it raise at $1B valuation to rerate the stock
"Bill has zero actual CEO experience but seems well-intentioned. His actions going forward will define him."
A vocal shareholder—who claims to have built a $1B+ revenue company with 90% market share—unloaded on Innventure management, calling out former CEO Otworth for alleged fraud, unjust enrichment suits, and installing an "inexperienced patsy" as his successor.
Key allegations:
• Share count ballooned from ~50M to 80M+ through "perpetual dilution"
• Management enriched insiders via related-party deals, bogus stock grants, and undisclosed payments to Vital Energy drink
• Despite Accelsius's last funding round implying $INV should trade above $3/share, stock languishes at a "massive discount" due to management reputation
The bright spot: Accelsius, the two-phase cooling play led by Josh Claman, is "in pole position" and could hit $4B market cap if execution continues.
The shareholder's prescription for new CEO Bill Grieco:
1. Fire CFO Roland Austrup to "clear the stench"
2. Slash overhead 95% to $3M/year max
3. Sell or shut down AeroFlex and Refinery
4. Stop dilution, related-party transactions, and claw back Vital Energy payments
5. Get out of Accelsius's way—let it raise at $1B valuation to rerate the stock
"Bill has zero actual CEO experience but seems well-intentioned. His actions going forward will define him."